Pathway to Cures Announces Two New Board Members

Pathway to Cures (P2C) announces two new members to its board of directors, Sharon Richardson, PhD, a Director on the National Bleeding Disorders Foundation Board, and Philip M. Gattone, M.Ed., President and CEO of the National Bleeding Disorders Foundation.

Pathway to Cures is the venture philanthropy fund for the National Bleeding Disorders Foundation (NBDF) focused on investing in emerging biotech companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community. Inheritable blood and bleeding disorders include rare and ultra-rare blood disorders, hemophilia A and B, von Willebrand disease, Sickle Cell disease, anemia, clotting disorders, and other hematological disorders, affecting more than 20 million people worldwide.

Sharon Richardson, PhD, is a result-driven strategist with 28 years of experience in the pharmaceutical industry as a medical affairs leader committed to creating healthier communities through scientific exchange, patient advocacy, and community engagement.

“P2C offers a unique opportunity for the National Bleeding Disorders Foundation to leverage their 75 years of serving people living with blood and bleeding disorders,” said Sharon Richardson. “It is a privilege to lend my time and assistance to advance the science and treatment options available to our community and to work alongside this talented and dedicated group of staff and volunteers.”

“Sharon has led a life of selfless service to others and has used her strong leadership skills to make a difference for our community.” said Phil Gattone “We are thrilled to have Sharon join the Pathway to Cures Board and look forward to working with her to make a positive impact in more lives.”

Philip M. Gattone, M.Ed., joined the National Bleeding Disorders Foundation as president and chief executive officer earlier this year. Gattone is a seasoned leader dedicated to amplifying the impact of nonprofit organizations through his distinctive blend of leadership and strategic insight. He has served as a senior executive in local, regional, national, and global nonprofit organizations and healthcare companies.

“We’re honored and delighted to have Sharon and Phil supporting our efforts for the inheritable blood and bleeding disorders community!” said Teri Willey, Managing Director of the Venture Philanthropy Fund “Their knowledge and experience will enhance our ability to ensure there are more therapies and cures available for our community.”

About Pathway to Cures

Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation created to accelerate the development of cures across all inheritable blood and bleeding disorders. In collaboration with other organizations, P2C invests in innovative therapies and technologies, leveraging the deep resources and scientific community relationships of the National Bleeding Disorders Foundation. By reinvesting proceeds from investments back into the Fund, P2C will amplify the investment impact, support promising biotech companies, and build a portfolio of investments that further the mission of the National Bleeding Disorders Foundation. For more information, visit www.pathwaytocures.org or contact Renee Peck at rpeck@pathwaytocures.org.

About National Bleeding Disorders Foundation

The National Bleeding Disorders Foundation (NBDF) is dedicated to finding cures for inheritable blood and bleeding disorders and addressing and preventing these disorders' complications through research, education, and advocacy, enabling people and families to thrive. Today, NBDF serves people across the United States with all bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and platelet disorders. The foundation also supports a network of 50 chapters across the country. To learn more, visit www.bleeding.org and follow NBDF across social media @nbd_foundation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905647406/en/